Stock events for Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics' stock price has increased significantly, with a 525.00% increase between March 4, 2025, and March 3, 2026. The stock jumped 36.3% following a clinical trial collaboration with Erasca. Tango Therapeutics reported its Q4 and full-year 2025 financial results, with $343.1 million in cash and collaboration revenue of $62.4 million. The company is on track to initiate a pivotal study for vopimetostat monotherapy in 2026. Malte Peters was appointed as the new CEO, and Sung Lee joined the Board of Directors. Mizuho initiated coverage with an outperform rating, and Stifel maintained its Buy rating. Management has been presenting at major healthcare conferences.
Demand Seasonality affecting Tango Therapeutics, Inc.’s stock price
There is no discernible demand seasonality for Tango Therapeutics, Inc.'s products and services. The demand for their investigational therapies is driven by the progression of clinical trials, regulatory approvals, and the unmet medical needs in specific cancer populations.
Overview of Tango Therapeutics, Inc.’s business
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision oncology therapies. They operate in the healthcare sector, leveraging synthetic lethality to identify novel drug targets, particularly for tumor suppressor gene loss. Their major product candidates include TNG908 (Vopimetostat), TNG462, TNG260, TNG348, and TNG456, targeting various cancers.
TNGX’s Geographic footprint
Tango Therapeutics, Inc. primarily conducts its business activities in the United States, with its headquarters located in Boston, Massachusetts.
TNGX Corporate Image Assessment
Tango Therapeutics' brand reputation is largely positive due to advancements in its clinical pipeline and strategic collaborations. Positive clinical developments and strategic partnerships have generated investor interest. The company's financial stability and leadership changes have also positively impacted its reputation. TNGX has significantly outperformed the market, indicating strong investor confidence.
Ownership
Tango Therapeutics, Inc. has significant institutional ownership, with 203 institutional owners and shareholders holding 153,680,985 shares. Major owners include Farallon Capital Management Llc, Boxer Capital Management, LLC, and Ecor1 Capital LLC, which is the largest individual shareholder. Institutional shareholders hold 128.08% of the stock, insiders hold 61.80%, and retail investors hold 0.00%.
